DALLAS, Aug. 4, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotechnology company Inovio Biomedical Corp. (AMEX:INO). The report includes financial, comparative and investment analyses and pertinent industry information you need to know to make an educated investment decision.
The investment report on Inovio Biomedical Corp. (AMEX:INO) should be of particular interest to other biotechnology companies: Introgen Therapeutics Inc. (Pink Sheets:INGNQ), Targeted Genetics Corp. (Nasdaq:TGEN), Amgen Inc. (Nasdaq:AMGN) and Biogen Idec Inc. (Nasdaq:BIIB).
It is available at: http://www.beaconequity.com/i/INO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Inovio Biomedical Corp. (INO) is a developer, manufacturer and marketer of vaccines through proprietary electroporation-based DNA technologies for preventive and therapeutic cancer and chronic infectious disease treatments. The Company operates through three subsidiaries: Genetronics Inc., Inovio AS and Inovio Asia Pte. Ltd. In June 2009, the Company merged with VGX Pharmaceuticals.
In the report, the analyst notes:
"The Company has received a lot of attention from investors due to the response to the rapid spread of the H1N1 virus reported by the WHO, which recent elevated its warning to world pandemic level six. Additional investor interest followed the Company's announcement that it has shown that its experimental H1N1 vaccine tested 100% effective against the virus in mice and pigs.
"The Company's inventory of promising drug therapy candidates also includes anti-HIV drugs. INO's compelling preclinical evidence that its proprietary DNA vaccine candidates are ready for clinical trials was confirmed by the National Institute of Allergy and Infectious Diseases, which awarded a $23.5 million grant to INO to continue research into DNA vaccines against HIV."
To read the entire report visit: http://www.beaconequity.com/i/INO
See what investors are saying about all these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.